Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
October 10, 2023 16:45 ET
|
Knight Therapeutics
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies
October 02, 2023 16:30 ET
|
Knight Therapeutics
MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s...
Knight Therapeutics Reports Second Quarter 2023 Results
August 10, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial...
Notice of Knight Therapeutics' Second Quarter 2023 Results Conference Call
August 03, 2023 20:32 ET
|
Knight Therapeutics
MONTREAL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2023...
Knight Announces Normal Course Issuer Bid
July 12, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today...
Knight to Present at the Jefferies 2023 Healthcare Conference in New York City
June 02, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, June 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-America (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia,...
Knight Therapeutics Reports First Quarter 2023 Results
May 11, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial...
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
May 10, 2023 17:42 ET
|
Knight Therapeutics
MONTREAL, May 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the...
Knight to Present at the 2023 RBC Capital Markets Global Healthcare Conference in New York City
May 09, 2023 13:00 ET
|
Knight Therapeutics
MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia,...
Notice of Knight Therapeutics' First Quarter 2023 Results Conference Call
May 04, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, May 04, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2023...